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Abstract
Shortening the turn-around time (TAT) of positive blood culture (BC) identification (ID) and
susceptibility results is essential to optimize antimicrobial treatment in patients with sepsis.
We aimed to evaluate the impact on antimicrobial prescription of a modified workflow of pos-
itive BCs providing ID and partial susceptibility results for Enterobacteriaceae (EB), Pseu-
domonas aeruginosa and Staphylococcus aureus on the day of BC positivity detection. This
study was divided into a pre-intervention period (P0) with a standard BC workflow followed
by 2 intervention periods (P1, P2) with an identical modified workflow. ID was performed
with MALDI-TOF MS from blood, on early or on overnight subcultures. According to ID
results, rapid phenotypic assays were realized to detect third generation cephalosporin
resistant EB/P. aeruginosa or methicillin resistant S. aureus. Results were transmitted to the
antimicrobial stewardship team for patient’s treatment revision. Times to ID, to susceptibility
results and to optimal antimicrobial treatment (OAT) were compared across the three study
periods. Overall, 134, 112 and 154 positive BC episodes in P0, P1 and P2 respectively
were included in the analysis. Mean time to ID (28.3 hours in P0) was reduced by 65.3%
in P1 (10.2 hours) and 61.8% in P2 (10.8 hours). Mean time to complete susceptibility
results was reduced by 27.5% in P1 and 27% in P2, with results obtained after 32.4 and
32.6 hours compared to 44.7 hours in P0. Rapid tests allowed partial susceptibility results to
be obtained after a mean time of 11.8 hours in P1 and 11.7 hours in P2. Mean time to OAT
was decreased to 21.6 hours in P1 and to 17.9 hours in P2 compared to 36.1 hours in P0.
Reducing TAT of positive BC with MALDI-TOF MS ID and rapid susceptibility testing
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accelerated prescription of targeted antimicrobial treatment thereby potentially improving
the patients’ clinical outcome.
Introduction
Sepsis is a frequent and severe condition associated with high morbidity and mortality rates.
According to the US Centers of Disease Control and Prevention, with over 1 million cases of
sepsis occurring each year, sepsis is the ninth leading cause of disease-related deaths in the
USA [1]. Prevention, rapid accurate diagnostic tests and innovative treatments constitute the
key interventions of a multimodal approach aimed to improve sepsis outcome. The clinical lab-
oratory plays a key role in the diagnosis of bloodstream infections (BSI) and reducing time to
identification and susceptibility is a major goal. The rapid availability of results should allow
early administration of targeted antimicrobial treatment hereby potentially improving clinical
outcome and also reducing length of hospital stay and associated costs [2]. More rapid optimal
therapy furthermore limits antibiotic use and the development of resistance [3,4].
Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF
MS) has proven over the years to be a rapid and accurate universal method for the identifica-
tion of microorganisms [5]. Various studies have shown that the use of MALDI-TOF MS both
decreases the time to organism identification and to effective antibiotic therapy [6,7,8,9]. How-
ever antimicrobial susceptibility testing is also essential for selecting the optimal treatment.
Rapid resistance testing methods have been introduced in clinical microbiology laboratories
for the detection of third generation cephalosporin-resistant Enterobacteriaceae (EB) and Pseu-
domonas aeruginosa or for the detection of methicillin resistance in Staphylococcus aureus
[10,11,12,13]. These partial susceptibility tests have been validated for their diagnostic perfor-
mance although their clinical impact has not been thoroughly assessed.
At the Cliniques universitaires St Luc—UCL we set up a routine laboratory procedure for
positive blood cultures integrating MALDI-TOFMS identification and rapid susceptibility test-
ing allowing earlier result communication (i.e.: on the day of positivity detection) [14]. This
modified workflow was conceived so as to be applicable in a routine clinical setting with a
major consideration towards cost-benefit ratio and reduced hands-on time.
The objectives of this study were to measure the time impact of a modified laboratory posi-
tive blood culture workflow on the availability of identification and susceptibility results as well
as on the time to administration of the optimal antimicrobial treatment.
Materials and Methods
Study design
This study was conducted at the Cliniques universitaires St Luc—UCL in Brussels, Belgium, a
964-bed tertiary hospital. This intervention study included three distinct study periods between
September 2013 and November 2014. A standard workflow was applied during the pre-inter-
vention period (P0) (September 2013 to November 2013). A modified workflow was identically
applied during both intervention periods: period 1 (P1) (from February 2014 to April 2014)
and period 2 (P2) (from September 2014 to November 2014). In-between the three periods,
laboratory technicians were trained on the modified workflow and multiple educational meet-
ings were held with the antimicrobial stewardship team of the hospital. This team included 2
infectious disease physicians and 1 intensive care practitioner.
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All episodes of positive blood cultures occurring in adult patients (18 years), based on
alerts of the BACTEC FX automated system (Becton Dickinson, Franklin Lakes, NJ, USA) and
yielding the growth of a single bacteria or yeast validated for identification with MALDI-TOF
MS were included. Any positive blood culture with the same pathogen within one week of a
previously confirmed blood culture in the same patient was considered as part of the same epi-
sode. Microbiological data of the positive blood culture episodes were recorded from the labo-
ratory information system and patients’medical records were reviewed for the collection of
demographic characteristics and for antibiotic treatment administrative data. The classification
of bacteremic episodes into BSI or into contaminations was defined according to the US Cen-
ters for Disease Control and Prevention/National Healthcare Safety Network definitions of
bloodstream infection events [15]. Patients who died or were transferred to another hospital
between blood culture sampling and time to detection as well as patients benefiting from pallia-
tive care were excluded from the study.
Identification and susceptibility methods
Identification was performed by MALDI-TOF MS on a MicroFlex LT platform (Bruker Dalto-
nik, Bremen, Germany). The acquired bacterial spectra were analyzed in the MALDI Biotyper
3.0 software with database version 3.1.2 and bearing the spectra of 4,111 cellular organisms.
According to the selected workflow (detailed below) and the time of blood culture positivity
detection, identification was performed following one of the three protocols namely (1) direct,
(ii) early and (iii) subculture MALDI-TOFMS identification (ID). Direct MALDI-TOFMS ID
from positive blood culture fluid with the commercial Sepsityper kit (Bruker Daltonik, Bremen,
Germany) performed according to Morgenthaler et al. and early MALDI-TOF MS ID on a
young subculture (5 hours) as validated by Verroken et al., allowed result reporting on the
same day as blood culture positivity detection [14,16]. MALDI-TOF MS ID on an overnight
subculture led to a result the day following detection [17]. MALDI-TOF MS identification
result scores were interpreted according to former publications that validated each method
[14,16,17].
Antimicrobial susceptibility testing (AST) for staphylococci, enterococci and EB was per-
formed using the automated Phoenix system (Becton Dickinson, Franklin Lakes, NJ, USA)
requiring 6–8 hours to complete results. AST of all other bacteria (anaerobes, Corynebacteria-
ceae, non fermenters, streptococci) was performed by disk diffusion using filter paper disks
(Bio-Rad, Marnes-la-Coquette, France) and results were read after 18 hours following
EUCAST guidelines [18]. According to the selected workflow and the time of blood culture
positivity detection, AST was performed either directly from the blood culture fluid according
to Beuving et al. either on an early subculture or on an overnight subculture [19]. Molecular
testing was done afterwards on all third generation cephalosporin-resistant and carbapenem-
resistant EB and P. aeruginosa for the detection of extended-spectrum β-lactamases (ESBL)
and of carbapenemases [20,21].
Partial susceptibility testing performed during the intervention periods, included the
βLACTA Test (βLT) (Bio-Rad, Marnes-la-Coquette, France) and the PBP2a Culture Colony
Test (PBP2a) (Alere, Scarborough, ME, USA). βLT was performed from positive blood cultures
identified with EB (excluding chromosomal AmpC producers) and P. aeruginosa leading to the
detection of resistance to third generation cephalosporins within 30 minutes. PBP2a was per-
formed on S. aureus identified blood cultures allowing the detection of methicillin-resistant S.
aureus (MRSA) strains within 15 minutes. According to the time of blood culture positivity
detection, partial susceptibility testing was performed directly from blood (on the bacterial
Clinical Impact of a Reviewed Blood CultureWorkflow
PLOSONE | DOI:10.1371/journal.pone.0156299 May 26, 2016 3 / 15
pellet obtained following centrifugation of a separator gel tube), or alternatively from early or
overnight subcultures following the manufacturer’s instructions.
Positive blood culture standard and modified laboratory workflow
The microbiology laboratory runs 7days/7 from 8 AM to 6 PM with a more limited activity
(Gram staining and inoculation of positive blood cultures only) between 6 PM and 0 AM. The
incubation of blood cultures is performed at any time of the day every day (i.e. 24/7).
During all three study periods, Gram staining was similarly performed at the time of
blood culture positivity detection and immediately communicated by phone to the treating
physicians (except between 0 AM and 8 AM). The laboratory workflow of the positive blood
culture bottles according to their time of positivity detection during P0, P1 and P2 is detailed
in Fig 1.
During phase P0, the standard workflow included subculture MALDI-TOF MS ID on day 1
followed by AST with results available on day 2 of positive blood culture detection. A direct
AST by Phoenix automate was performed when Gram-negative rods were detected on Gram
staining and susceptibility results were made available on day 1 if an EB was identified.
During the intervention periods (P1 and P2), all blood cultures that were found positive
before 10AM on day 0 benefited from the modified workflow that included early subculture
MALDI-TOF MS ID, selectively followed by partial susceptibility testing realized from early
subculture. For blood cultures detected positive between 10 AM and 3 PM, MALDI-TOF
MS ID and partial susceptibility testing was directly performed on blood. ID results were
available by 5 PM on the same day. Subsequent AST performed on blood/early subculture
allowed complete susceptibility results to be accessible on day 1. Because of limited laboratory
staff resources during evening and night hours, blood cultures detected positive after 3 PM
were handled using the standard workflow for identification and complete AST. Partial sus-
ceptibility testing on subcultured EB, P. aeruginosa and S. aureus was performed on day 1
after identification results’ availability, further finalized by complete AST results obtained on
day 2.
Twice daily, at 11 AM and 5 PM, all newly available identification, partial or complete
susceptibility results were notified by phone to the antimicrobial stewardship team without dis-
tinction of the study periods. Recommendations for (semi-) empirical and final targeted antibi-
otic treatment provided to the prescribing physicians by the antimicrobial stewardship team
were based on local antibiotic guidelines and remained similar across all study phases.
Outcomes
The study objectives were to analyze microbiological and clinical outcomes following imple-
mentation of the modified laboratory workflow applied on positive blood cultures. In order
for analyses to be comparable between phases, we excluded from the analysis any blood cul-
ture from P0 that turned positive at a time of the day that would have made them ineligible
for the modified workflow if it had been applied at that time. Similarly, only the positive blood
cultures that benefited from the modified blood culture workflow during P1 and P2 were
included in the final analysis. Main microbiological outcome indicators were time to identifi-
cation and time to partial/ complete susceptibility results across the three study periods. Main
clinical outcome indicator was time to patient’s administration of the optimal antimicrobial
BSI treatment (OAT) in the three periods. The OAT was defined as the final and targeted
drug prescribed by the treating physician following the antimicrobial stewardship team’s
guidelines. Each OAT was labeled as either the initiation of an antimicrobial treatment, a de-
escalation of the (semi-) empirical treatment, a spectrum broadening of the (semi-) empirical
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treatment or a switch of regimen of the (semi-) empirical treatment. The empirical treatment
was defined as the antimicrobial drug administered before availability of any laboratory
results (Gram stain, identification or susceptibility). The categorization as semi-empirical
treatment was based on partial laboratory results (Gram and/or identification and/or partial
susceptibility).
All time measurements started from the instant the blood culture bottle was detected posi-
tive by the BACTEC FX automated system. BSI episodes where the modified workflow tech-
niques did not yield acceptable results (lack of identification results, uninterpretable/erroneous
partial susceptibility testing results) as well as contaminations were excluded from the outcome
analyses.
Data handling and statistical analyses
Descriptive analyses were first performed on our data to obtain summary statistics for the ther-
apeutic and clinical outcome of interests, as well as patient characteristics. Proportions and
Fig 1. Laboratory workflow of positive blood culture bottles according to time of positivity detection during pre-intervention
and intervention periods. AST, antimicrobial susceptibility testing; BC, blood culture; βLT, βLACTA test; EB, Enterobacteriaceae; ID,
identification; MALDI-TOF MS, matrix-assisted laser desorption ionization time-of-flight mass spectrometry; PBP2a, PBP2a Culture
Colony Test. *: AST was directly performed from positive blood culture fluid when Gram staining identified a Gram-negative rod. Grey
squares highlight the accelerated identification and susceptibility tests applied in the modified workflow.
doi:10.1371/journal.pone.0156299.g001
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means of binary and continual variables were compared between P0, P1 and P2 using chi-
square tests, t-tests and analysis of variance (ANOVA). We then explored the distribution of
time to identification, time to susceptibility and time to OAT as a function of intervention
phases and other covariates of interests using a negative binomial regression model, which is a
Poisson model accounting for overdispersion. Covariates significant at P<0.05 in univariable
analysis were considered for multivariable analysis in the model exploring time as a function of
phases.
Ethics statement
The study protocol was approved by the Ethical Committee of the Cliniques universitaires St
Luc—UCL (National number: B403). Information from microbiological and clinical files was
anonymously analyzed and did not require patients’ informed consent.
Results
The study included a total of 847 positive blood cultures counting for 272, 266 and 309 epi-
sodes during P0, P1 and P2, respectively (Fig 2). The exclusion of all episodes detected positive
outside the modified workflow scheme hours, lead to the selection of 199 episodes (73%) in P0,
188 (71%) in P1 and 234 (76%) in P2. With the focus of our study set on BSI, all contamina-
tions were also discarded. Ultimately microbiological and clinical outcomes were compared for
134, 112 and 154 BSI in P0, P1 and P2 respectively as we likewise excluded 23 BSI in P1 and 20
BSI in P2 with unsuccessful results through speeded-up testing.
Demographic characteristics including gender, age, comorbidities selection and source of
bacteremia were compared across the three study periods. Overall no statistical differences
were observed with an exception for age and diabetes. Patients in P1 and P2 were significantly
older and diabetes was more frequent than in P0. In all three periods, the urinary tract, the gas-
tro-intestinal tract and the central venous catheter accounted for the main sources of BSI.
Microbiological data and antimicrobial resistance of all BSI are detailed in Table 1. Across the
three study periods, non-natural AmpC EB and staphylococci were the most frequent isolated
microorganisms. Prevalence of methicillin resistance among S. aureus was 7.1% in P0, 8.3% in
P1 and 14.3% in P2. Prevalence of third generation cephalosporin resistance among EB (natu-
ral and non-natural AmpC producers) was 16.9%, 17.6% and 22.6% in P0, P1 and P2 respec-
tively. No carbapenem-resistant EB were isolated in any study period and a single carbapenem-
resistant P. aeruginosa isolate was identified in P1.
Rapid identification and susceptibility test performances
Failure of identification with direct/early MALDI-TOF MS led to the exclusion of respectively
17 and 18 BSI in P1 and P2 (Table 1). Insufficient log scores or the absence of spectral peaks
were at the origin of all missed identifications. Anaerobes and yeast were the main non-identi-
fied microorganisms. There were no misidentifications. In conclusion, considering all BSI
managed with the modified workflow in both intervention periods, direct and early MALDI--
TOF MS allowed a reliable species identification for 82.0% and 87.0% episodes, respectively.
βLT performed on 165 BSI (P1 and P2 combined) yielded 24 positive, 140 negative and 1
uninterpretable test result due to an incoherent color change of the chromogenic test. All posi-
tive βLT results were found in non-natural AmpC EB isolates displaying third generation ceph-
alosporin resistance by complete AST results and subsequently confirmed as ESBL producers.
In 7 cases, βLT yielded false-negative results since complete AST and molecular testing identi-
fied 6 AmpC producing Escherichia coli and 1 VIMmetallo-beta-lactamase-producing P. aeru-
ginosa, all resistant to third generation cephalosporin. Globally, sensitivity and specificity of
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βLT were respectively 77.4% and 100%. No erroneous or uninterpretable results were observed
with PBP2a testing. Performed on 26 S. aureus BSI in P1 and P2, PBP2a was able to detect all 3
MRSA strains (sensitivity and specificity of 100%). Ultimately, 8 BSI (6 in P1 and 2 in P2) were
discarded from outcome analysis due to erroneous/uninterpretable rapid test results.
Microbiological outcomes
Microbiological outcomes are presented in Table 2. Time to identification of positive blood cul-
ture episodes was significantly reduced in P1 and P2 compared to P0. The mean time was
28.3 hours in P0 and was reduced by 65.3% in P1 (10.2 hours) and 61.8% in P2 (10.8 hours)
(P<0.0001). In P1, subculture, early and direct MALDI-TOF MS were respectively performed
on 23/112 (20.5%), 65/112 (58.0%) and 24/112 (21.5%) blood cultures. During P2, 32/154
(20.8%) subculture, 96/154 (62.3%) early and 26/154 (16.9%) direct MALDI-TOF MS identifi-
cations were realized. Combining P1 and P2, mean time to identification when applying sub-
culture, early and direct MALDI-TOF MS ID protocols were respectively 16.5, 10.7 and 3.8
hours. Fig 3A shows the distribution of BSI identified within 12, 24 and 48 hours for the 3 peri-
ods and highlights the higher proportion of BSI identified within 12 and 24 hours in P1 and P2
compared to P0. As for identification, the mean time to complete susceptibility results was
Fig 2. Flowchart of adult monomicrobial blood culture episodes included during pre-intervention and intervention periods. BC, blood culture;
BSI, bloodstream infections.
doi:10.1371/journal.pone.0156299.g002
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Table 2. Time to identification and time to partial/complete susceptibility results of all bloodstream
infections during pre-intervention and intervention period 1 and 2.
Time to identiﬁcation
Phase Method n BSI Mean time to ID (hours)
P0 TOTAL 134 28.3
Subculture MALDI-TOF MS 134 28.3
Early MALDI-TOF MS - -
Direct MALDI-TOF MS - -
P1 TOTAL 112 10.2
Subculture MALDI-TOF MS 23 15.9
Early MALDI-TOF MS 65 10.6
Direct MALDI-TOF MS 24 3.6
P2 TOTAL 154 10.8
Subculture MALDI-TOF MS 32 17.1
Early MALDI-TOF MS 96 10.7
Direct MALDI-TOF MS 26 4.0
Time to partial susceptibility result
Phase Method n BSI Mean time to partial AST result (hours)
P1 TOTAL 72 11.8
Culture βLT 20 17.9
Young subculture βLT 29 11.2
Direct βLT 12 3.7
Culture PBP2a 3 15.3
Young subculture PBP2a 6 12
Direct PBP2a 2 2
P2 TOTAL 108 11.7
Culture βLT 29 16.8
Young subculture βLT 50 11.1
Direct βLT 15 3.6
Culture PBP2a 4 20.2
Young subculture PBP2a 9 8.8
Direct PBP2a 1 6
Time to complete susceptibility result
Phase Method n BSI Mean time to complete AST result (hours)
P0 TOTAL 134 44.7
Phoenix from subculture 58 46.9
Phoenix from young subculture - -
Direct Phoenix 48 28.3
Manual testing from subculture 28 68.3
Manual testing from young subculture - -
P1 TOTAL 112 32.4
Phoenix from subculture 28 41.2
Phoenix from young subculture 23 32.2
Direct Phoenix 45 25.6
Manual testing from subculture 7 49.1
Manual testing from young subculture 9 27.3
P2 TOTAL 154 32.6
Phoenix from subculture 34 41.6
Phoenix from young subculture 81 29.9
(Continued)
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reduced by 27.5% in P1 and 27% in P2 with results after 32.4 and 32.6 hours compared to 44.7
hours in P0 (P<0.0001). Fig 3B highlights the reduced time to complete susceptibility in P1
and P2 compared to P0. The larger proportion of BSI with complete AST results within 48
hours in P1 and P2 could be assigned to the extension of direct AST to staphylococci and
enterococci and the integration of manual/automated testing on young subcultures as detailed
in Table 2. Rapid βLT and PBP2a allowed partial susceptibility results after a mean time of 11.8
hours in P1 and after 11.7 hours in P2.
Clinical outcomes
Time to administration of the OAT was significantly reduced during the intervention periods
with mean times of 21.6 hours in P1 and 17.9 hours in P2 compared to 36.1 hours in P0
(P<0.0001). Fig 3C displays the higher proportion of BSI optimally treated within the first 24
hours in P1 and P2 versus P0. The faster identification and susceptibility test results of the
modified workflow in P1 would have allowed earlier initiation of a targeted antimicrobial
treatment in 43/112 BSI episodes (38.4%) yet the antimicrobial stewardship team considered
laboratory results and consequently adapted therapy in only 22 BSI (19.6%). Similarly in P2,
64/154 BSI (41.6%) episodes had speeded-up laboratory results theoretically allowing the
accelerated onset of the OAT yet an effective therapy switch was introduced only in 45 BSI
episodes (29.2%). Table 3 illustrates all BSI episodes from P1 and P2 that benefited from an
effective speeded-up antimicrobial treatment tailoring following rapid laboratory test results.
Early and direct MALDI-TOF MS identification majorly contributed to the earlier initiation
of antibiotic therapy in BSI episodes without empirical treatment. All strains identified in
these 18 BSI episodes were Gram-positive microorganisms. Concomitant PBP2a test results
assisted to the early onset of the OAT in 4 methicillin-susceptible (1 in P1 and 3 in P2) and 2
methicillin-resistant S. aureus BSI (1 in P1 and 1 in P2). In BSI with an inappropriate empiri-
cal treatment, rapid identification and partial susceptibility testing results equally facilitated
treatment tailoring. Thereby 13 positive βLT results (5 in P1 and 7 in P2) led to the acceler-
ated OAT administration through antimicrobial spectrum broadening or a switch to a differ-
ent antimicrobial regimen. Conversely, 14 negative ßLT and PBP2a results (1 in P1 and 13 in
P2) allowed faster treatment de-escalation in BSI with an appropriate empirical BSI treat-
ment. For 69 BSI in P1 and 90 BSI in P2, the laboratory results inherent to the modified
workflow brought no additional information enabling the tailoring of the administered
empirical antibiotic treatment. Those episodes included inter alia all BSI with an empirical
treatment remaining unchanged because ultimately evaluated as the OAT (“No change” cate-
gory in Fig 3C).
Table 2. (Continued)
Direct Phoenix 22 22.2
Manual testing from subculture 8 52.2
Manual testing from young subculture 9 30.9
AST, antimicrobial susceptibility testing; βLT, βLACTA test; BSI, bloodstream infection; ID, identiﬁcation;
MALDI-TOF MS, matrix-assisted laser desorption ionization time-of-ﬂight mass spectrometry; P0, pre-
intervention period; P1, intervention period 1; P2, intervention period 2; PBP2a, PBP2a Culture Colony
Test.
doi:10.1371/journal.pone.0156299.t002
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Fig 3. Distribution of the bloodstream infections over time in the three study periods according to their
microbiological and clinical outcomes. (A) Distribution of the bloodstream infections identified within defined time
lapses. (B) Distribution of the bloodstream infections according to the time of complete susceptibility result availability.
(C) Distribution of the bloodstream infections benefitting from the optimal antimicrobial treatment within defined time
lapses. The “No change” category defines bloodstream infections optimally treated before the detection of positive
blood culture. BSI, bloodstream infection.
doi:10.1371/journal.pone.0156299.g003
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Discussion
The modified workflow evaluated in our study included MALDI-TOF MS identification, rapid
partial susceptibility tests (PBP2a and ßLT) for S. aureus, EB and P. aeruginosa, and manual/
automated complete susceptibility testing. Additionally, all tests could be carried out from
three different supports (blood culture pellets, early subcultures and overnight subcultures)
depending on the timeframe during which the blood culture bottle was detected positive.
Through the set-up of this workflow, we aimed to maximize the proportion of microbiological
results made available to the clinicians within the same day of positive blood culture detection
in balance with hands-on time of tests, technician availability and reagent costs. All blood cul-
tures detected positive before 10 AM yielded sufficient microbial growth for performing the
tests directly from subculture colonies in the early afternoon. The high performances of early
MALDI-TOF MS with 87% correct identification and it’s ease of use, requiring no fastidious
pre-treatment nor any additional cost, makes it an excellent alternative in comparison to direct
MALDI-TOF MS [22]. On the other hand, blood cultures detected after 10 AM did not provide
sufficient growth in the early afternoon for rapid testing and thus required direct identification.
With reliable results obtained in 82%, we achieved the global 80% performance of the Sepsity-
per kit calculated in the meta-analysis of Morgenthaler et al. [16]. Blood cultures detected posi-
tive between 3 PM and 0 AM were identified by classical subculture MALDI-TOFMS on the
following day. This is due to the fact that our microbiology laboratory is not fully operational
on a 24-hour basis as only limited work is realized from ongoing analyses during the late after-
noon and night. Eveillard et al. demonstrated the usefulness of performing bacterial identifica-
tion and AST 24h a day with an earlier initiation of appropriate treatment in 22.6% [23]. But in
this current era of global healthcare cost savings, extending laboratory working staff is unlikely
and the availability on site of a clinician during late-day and night hours that would adjust anti-
microbial treatment according early laboratory results also seems very unlikely. We therefore
believe that the proposed identification workflow may constitute a good alternative as speeded-
Table 3. Effective antibiotic treatment tailoring of bloodstream infections in both intervention periods following accelerated laboratory results.
BSI without
empirical treatment
BSI with
inappropriate
empirical treatment
BSI with appropriate
empirical treatment
Intervention period (n BSI) P1 (10) P2(8) P1 (8) P2 (16) P1 (4) P2 (21)
Subsequent antimicrobial treatment tailoring
Initiation 10 8 - - - -
De-escalation - - - - 3 17
Spectrum broadening - - 4 13 - -
Switch of regimen - - 4 3 1 4
Speeded-up test at the origin of treatment tailoring
Direct/early MALDI-TOF MS ID 10 8 3 7 2 4
Rapid partial susceptibility testing
PBP2a 2* 4* - - 1 1
βLT - - 5 7 - 12
Direct/young subculture complete AST - - - 2 1 4
AST, antimicrobial susceptibiltiy testing; βLT, βLACTA test; BSI, bloodstream infection; ID, identiﬁcation; MALDI-TOF MS, matrix-assisted laser desorption
ionization time-of-ﬂight mass spectrometry; P1, intervention period 1; P2, intervention period 2; PBP2a, PBP2a Culture Colony Test.
*The rapid partial susceptibility test result contributed to a treatment tailoring in combination with the identiﬁcation test result.
doi:10.1371/journal.pone.0156299.t003
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up MALDI-TOF MS enabled identification results within 24 hours after positive blood culture
detection for> 95% of all BSI during the two intervention periods.
Alongside rapid partial susceptibility testing likewise provided contributive results on the
day of blood culture positivity detection. Despite the limited information, a partial susceptibil-
ity test result can give some valuable insight and help predicting the antibiotic phenotypic resis-
tance profile of an organism. Such information, when coupled with the knowledge of local
resistance epidemiology, can improve the prescription of targeted antibiotic treatment. PBP2a
testing yielded excellent performances as it detected all MRSA blood strains without any false
positive results being found. Additionally, 2 positive PBP2a results led to the earlier instaura-
tion of containment measures following the detection of a multi-resistant strain. On the other
hand, βLT performances are more nuanced as the test missed the detection of 7 third genera-
tion cephalosporin-resistant strains i.e. 6 AmpC producing E. coli and one VIM P. aeruginosa.
Previously, Walewski et al. underlined the low sensitivity of ßLT for the detection of chromo-
somal overproduced AmpC-type ß-lactamases but also of plasmid-encoded AmpC [13]. We
believe additional validation and improvement of the ßLT is necessary; until then caution
needs to be taken in the treatment adaptation of BSI episodes caused by non-natural AmpC
producing EB with a negative ßLT. The inability of ßLT to detect a VIM-producing P. aerugi-
nosa supported earlier observations made by Laurent et al. [11].
Our study approach distinguishes itself as it measures the clinical impact of a complete posi-
tive blood culture workflow rather than the isolated impact of a single identification or suscep-
tibility test. Several authors evaluated the impact of MALDI-TOF MS identification on
antimicrobial prescription in patients with bacteremia [6,7,8,9]. In the prospective trial of Vlek
et al., direct MALDI-TOF MS performed twice a day led to a median time to identification of
16.4 hours and was associated with 64% of the patients receiving appropriate treatment 24
hours after blood culture positivity [9]. Our study was similarly conducted but contained addi-
tional rapid identification and susceptibility techniques thereby reducing mean time to OAT
from 31.1 hours to 21.6 and 17.9 hours respectively in P1 and P2. Early and direct MALDI-
TOF MS identification mainly contributed to earlier initiation of antibiotic therapy in BSI epi-
sodes that had previously been considered as contaminations especially in non-critically ill
patients. Partial susceptibility test results led more often to the adjustment of an already admin-
istered antimicrobial therapy by streamlining or broadening the spectrum. Interestingly, we
observed a better empiric coverage during P2 versus P1 and P0 potentially influencing the
reduced time to OAT. This observation suggests that besides the effect of the modified work-
flow, other factors as for example an increasing consideration of rapid laboratory test results
over time by the antimicrobial stewardship team and a better adhesion to empiric treatment
guidelines might also have played a role in our study.
The division of the intervention phase into two sequential periods allowed us to evaluate the
clinician’s prescription behavior over time. Of all BSI with speeded-up microbiological results
enabling an accelerated prescription of OAT, 70.3% (45/64) benefited from an effective treat-
ment revision in P2 compared to 51% (22/43) in P1. Educational meetings between the two
intervention periods discussing rapid testing performances and partial outcome results possi-
bly could have led to an enhanced trust of the infection disease specialists and thereby might
have accounted for the improved time to OAT in P2 versus P1.
The modified workflow for the management of positive blood cultures outlined in the study
is a highly customized scheme adapted to our local working environment and in accordance
with our local resistance epidemiology. The transposition of this scheme in another setting
could have a different impact on the clinical outcomes depending on local microbiological and
resistance data and also influenced by the local antimicrobial treatment guidelines for septice-
mia. Beyond the proposal of an improved yet singular positive blood culture laboratory
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workflow, this study ultimately aims at arousing the interest of each clinical laboratory to reas-
sess positive blood culture management allowing speeded-up identification and susceptibility
results. Our workflow evaluated a non-exhaustive selection of identification and susceptibility
testing methods and can only be considered as a primary draft to be refined by each laboratory
according to specific local criteria. The selection of an identification method primarily depends
on the laboratory working hours. Alongside, rapid susceptibility tests should be selected based
on the local resistant epidemiology. In settings with high prevalence/incidence of carbapenem
resistance, laboratories should consider the introduction of a distinct rapid partial susceptibility
test for the detection of carbapenemases [24]. On the other hand, partial susceptibility tests
might have less impact in a clinical setting with very low resistance profiles.
In this study, we aimed to develop a refined applicable positive blood culture workflow inte-
grating rapid identification and susceptibility techniques hereby allowing an accelerated
microbial diagnosis and a reduced time to OAT. This integrated approach with the active coop-
eration of the antimicrobial stewardship team significantly improved the timeliness of targeted
treatment administration. Further work evaluating the potential impact of the modified work-
flow on mortality and morbidity, length of hospitalization and medical costs is suggested.
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